nach oben

Erschienen in:

13.08.2018 | Koronare Herzerkrankung | FORTBILDUNG . ÜBERSICHT

Plötzlich Thoraxschmerzen

Das akute Koronarsyndrom

verfasst von: Dr. med. Johannes Leschik, Prof. Dr. med. Timm Bauer

Erschienen in: MMW - Fortschritte der Medizin | Ausgabe 14/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das führende klinische Symptom der Erkrankung ist Angina pectoris: Ein Patient klagt typischerweise über ein retrosternales Druck- oder Schweregefühl, das in den linken Arm, den Hals bzw. Kiefer oder den Oberbauch ausstrahlt. Manche Patienten berichten auch nur über Kurzatmigkeit, Übelkeit, Erbrechen, Palpitationen oder Synkopen.

Hartley A, Marshall DC, Salciccioli JD et al. Trends in Mortality From Ischemic Heart Disease and Cerebrovascular Disease in Europe: 1980 to 2009. Circulation. 2016;133:1916–26CrossRefPubMed

Townsend N, Wilson L, Bhatnagar P et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37:3232–45CrossRefPubMed

Group EUCCS, Regitz-Zagrosek V, Oertelt-Prigione S et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37:24–34CrossRef

Campeau L. Letter: Grading of angina pectoris. Circulation. 1976;54:522–3PubMedCrossRef

Canto JG, Fincher C, Kiefe CI et al. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol. 2002;90:248–53CrossRefPubMed

Brieger D, Eagle KA, Goodman SG et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest. 2004;126:461–9CrossRefPubMed

Roffi M, Patrono C, Collet JP et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315CrossRefPubMed

Mackay MH, Ratner PA, Johnson JL et al. Gender differences in symptoms of myocardial ischaemia. Eur Heart J. 2011;32:3107–14CrossRefPubMed

Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77CrossRefPubMed

10.

Khera S, Kolte D, Gupta T et al. Temporal Trends and Sex Differences in Revascularization and Outcomes of ST-Segment Elevation Myocardial Infarction in Younger Adults in the United States. J Am Coll Cardiol. 2015;66:1961–72CrossRefPubMed

11.

Puymirat E, Simon T, Steg PG et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA. 2012;308:998–1006CrossRefPubMed

12.

Gorenek B, Blomstrom Lundqvist C, Brugada Terradellas J et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace. 2014;16:1655–73CrossRefPubMed

13.

Thiele H, Akin I, Sandri M et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377:2419–32CrossRefPubMed

14.

Widimsky P, Wijns W, Fajadet J et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. 2010;31:943–57CrossRefPubMed

15.

Chan AW, Kornder J, Elliott H et al. Improved survival associated with pre-hospital triage strategy in a large regional ST-segment elevation myocardial infarction program. JACC Cardiovasc Interv. 2012;5:1239–46CrossRefPubMed

16.

Armstrong PW, Gershlick AH, Goldstein P et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379–87CrossRefPubMed

17.

Boersma E, Primary Coronary Angioplasty vs. Thrombolysis G. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27:779–88CrossRefPubMed

18.

Scholz KH, Maier SK, Jung J et al. Reduction in treatment times through formalized data feedback: results from a prospective multicenter study of ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012;5:848–57CrossRefPubMed

19.

Knot J, Widimsky P, Wijns W et al. How to set up an effective national primary angioplasty network: lessons learned from five European countries. EuroIntervention. 2009;5:299–309PubMed

20.

Valgimigli M, Gagnor A, Calabro P et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385:2465–76CrossRefPubMed

21.

Kastrati A, Dibra A, Spaulding C et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J. 2007;28:2706–13CrossRefPubMed

22.

Larsen AI, Galbraith PD, Ghali WA et al. Characteristics and outcomes of patients with acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol. 2005;95:261–3CrossRefPubMed

23.

Lancellotti P, Price S, Edvardsen T et al. The use of echocardiography in acute cardiovascular care: recommendations of the European Association of Cardiovascular Imaging and the Acute Cardiovascular Care Association. Eur Heart J Cardiovasc Imaging. 2015;16:119–46CrossRefPubMed

24.

Mehta SR, Granger CB, Boden WE et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360:2165–75CrossRefPubMed

25.

Thiele H, Rach J, Klein N et al. Optimal timing of invasive angiography in stable non-ST-elevation myocardial infarction: the Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI (LIPSIA-NSTEMI Trial). Eur Heart J. 2012;33:2035–43CrossRefPubMed

26.

Granger CB, Goldberg RJ, Dabbous O et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163:2345–53CrossRefPubMed

27.

Bawamia B, Mehran R, Qiu W et al. Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. Am Heart J.2013;165:441–50CrossRefPubMed

28.

Theroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–11CrossRefPubMed

29.

Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–89CrossRefPubMed

30.

De Servi S, Goedicke J, Schirmer A et al. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care. 2014;3:363–72CrossRef

31.

Lindholm D, Varenhorst C, Cannon CP et al. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35:2083–93CrossRefPubMedPubMedCentral

32.

Bonaca MP, Bhatt DL, Steg PG et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133–42CrossRefPubMed

33.

Costa F, Tijssen JG, Ariotti S et al. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. J Am Heart Assoc. 2015;4:e002524PubMedPubMedCentralCrossRef

34.

Harrington RA, Becker RC, Cannon CP et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:670S–707SCrossRefPubMed

35.

Silvain J, Beygui F, Barthelemy O et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553CrossRefPubMedPubMedCentral

36.

Yusuf S, Mehta SR, Chrolavicius S et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–30CrossRefPubMed

37.

Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60CrossRefPubMed

38.

Dans AL, Connolly SJ, Wallentin L et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013;127:634–40CrossRefPubMed

39.

Gibson CM, Mehran R, Bode C et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375:2423–34CrossRefPubMed

40.

Chow CK, Jolly S, Rao-Melacini P et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation. 2010;121:750–8CrossRefPubMed

41.

LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35CrossRefPubMed

42.

Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372:2387–97CrossRefPubMed

43.

Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376:1713–22CrossRefPubMed

44.

Schwartz GG, Szarek M, Bhatt DL. Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab - ODYSSEY OUTCOMES. http://www.acc.org/latest-in-cardiology/clinical-trials/2018/03/09/08/02/odyssey-outcomes; zuletzt besucht: 2.7.2018

45.

Authors/Task Force M, Ryden L, Grant PJ et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87CrossRef

Titel: Plötzlich Thoraxschmerzen
Das akute Koronarsyndrom
verfasst von: Dr. med. Johannes Leschik
Prof. Dr. med. Timm Bauer
Publikationsdatum: 13.08.2018
Verlag: Springer Medizin
Schlagwörter: Koronare Herzerkrankung
Akutes Koronarsyndrom
ST-Hebungsinfarkt
Thoraxschmerzen
Acetylsalicylsäure
Acetylsalicylsäure
Clopidogrel
Prasugrel
Ticagrelor
Herzinfarkt
Erschienen in: MMW - Fortschritte der Medizin / Ausgabe 14/2018
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI: https://doi.org/10.1007/s15006-018-0022-2

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2018

Diabetiker nach Koronarsyndrom profitieren besonders

Volksseuche Nagelpilz

GOÄ: So steigern Sie über 2,3-fach

So geht es weiter mit der TI-Anbindung

Richtgrößenprüfungen sind im Grunde rechtswidrig

Ein Mann gibt sein ehemals bestes Stück verloren